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P eripheral artery disease (PAD) is largely prevalent andevident among the general population.1 PAD recognizes
multiple risk factors, and it is associated with an increased
risk of morbidity and mortality.1 Similarly, atrial fibrillation
(AF) is the most prevalent and incident arrhythmia, associated
with an increased risk for stroke and major cardiovascular
outcomes.2 In recent years, accumulating evidence suggests
that a strong relationship exists between PAD and AF.3 Both
the conditions share similar major risk factors and common
epidemiologic characteristics. Also, it is largely known that
the concomitant presence of these conditions significantly
increases the risk of major adverse events.3
Ankle-Brachial Index and AF
Some data suggest that a direct link can exist between the
presence of PAD and an increased risk of incident AF.4,5 In
particular, it has been reported that an inverse “dose-effect
response” relationship exists between ankle-brachial index
(ABI) and the risk of newly detected AF.6,7 ABI is a simple,
costless, and noninvasive test used as the first-line diagnostic
approach to PAD.1 Current guidelines recommend performing
an ABI evaluation for all patients who report suggestive
symptoms of PAD; an ABI value ≤0.90 is diagnostic for the
presence of PAD.1 An ABI value between 0.91 and 0.99 is
currently considered as “borderline,” requiring further assess-
ments.1 Furthermore, an ABI ≥1.40 still indicates a vascular
disease, although it is usually related to tunica media wall,
associated with diabetes mellitus.1 ABI is also considered a
strong marker of generalized atherosclerosis and cardiovas-
cular risk.1
In this issue of the Journal of the American Heart
Association (JAHA), Bekwelem and colleagues present an
analysis derived from the ARIC (Atherosclerosis Risk in
Communities) Study, about the association between PAD
and risk of new-onset AF.8 ARIC is a large, prospective,
epidemiologic study conducted in 4 US communities, aimed
to investigate causes and mechanisms of atherosclerosis, the
variation and interaction between relevant risk factors and
demographic variables, and the influence on long-term
outcomes.9 With 15 792 patients followed up for 20 years,
the ARIC Study published >2000 articles and represents a
robust study still providing relevant and reliable insights into
the pathophysiological mechanisms of atherosclerosis and its
clinical sequelae. In this new analysis, the authors reported
that diagnosis of PAD according to ABI classes is associated
with an incident diagnosis of AF. Indeed, patients with an ABI
≤0.90 had, after adjustment for age, sex, and race, an
increased risk of developing AF (hazard ratio [HR], 1.35; 95%
confidence interval [CI], 1.21–1.51). After full adjustment for
all the concomitant risk factors and cardiovascular comor-
bidities, despite being attenuated, the association remained
significant, with 13% increase in relative risk compared with
subjects with normal ABI (1.00–1.40).8
Conversely, patients with ABI ≥1.40 did not have an
increased risk of AF in both unadjusted and adjusted
analyses. These results, although assessed on a larger cohort,
substantially confirmed the previous data on the relationship
between ABI and incident AF.8 The article from Bekwelem and
colleagues reported that borderline ABI (0.91–0.99) is signif-
icantly associated with incident AF after both age-sex-race
adjustment (HR, 1.32; 95% CI, 1.16–1.50) and full adjustment
(HR, 1.14; 95% CI, 1.00–1.30).8 Conversely, although ABI
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≤0.90 remained associated with incident AF after age-sex-
race adjustment (HR, 1.43; 95% CI, 1.17–1.75), full adjust-
ment strongly attenuated the relationship (HR, 1.10; 95% CI,
0.90–1.34). The age-sex-race adjusted cubic spline also
proved the inverse dose-effect response between ABI and
risk of AF.8
Finally, the authors have been able to report that both
“pathological” ABI (≤0.90) and borderline ABI (0.91–0.99)
were associated with an increased risk for all-cause death,
compared with subjects with ABI of 1.00 to 1.40, in both
patients who developed and did not develop AF. The
magnitude of association was lower in patients who did not
develop AF and has also been found progressively lower from
pathological to borderline ABI.
This interesting article, beyond confirming the previous
evidence about the causal relationship between PAD and AF,
extends previous findings and adds significant knowledge
about this relevant issue. Indeed, the evidence that even
borderline ABI is associated both with incident AF and
increased all-cause death reinforces the concept that there is
a direct proportion between the entity of vascular disease and
the burden of risk for incident AF (and associated adverse
events). Also, it has been proved that borderline ABI is not
harmless and should be considered and assessed cautiously.
Accumulating Evidence for a New
Pathophysiological Paradigm
To date, 2 studies have analyzed the relationship between ABI
levels and risk of incident AF. O’Neal and colleagues6
performed an analysis from the MESA (Multi-Ethnic Study of
Atherosclerosis), a population-based study aimed at exploring
the characteristics of subclinical cardiovascular disease and
the relationship with risk factors that could predict its
progression to clinically overt disease. In that study, they
showed that PAD (defined as both ABI <1.00 and ABI >1.40)
was associated with incident AF. Also, although ABI <1.0
alone was still found associated with the risk of AF, ABI >1.40
showed a nonsignificant trend in association.6 Similar results
were also reported by Griffin and colleagues, who performed
an analogous analysis in the CHS (Cardiovascular Health
Study) cohort, an observational population-based study about
risk factors for cardiovascular disease and their influence in
disease progression in elderly (≥65 years) subjects.7
To obtain more robust evidence about the relationship
between PAD and AF, we merged together data coming from
these 3 large population-based studies: ARIC Study, MESA,
and CHS. To reach our aim, we performed a meta-analysis and
meta-regression of data coming from the 3 studies6–8 (Table),
including a total of 26 505 subjects. Bayesian meta-analyses
under heterogeneity were conducted by means of hierarchical
(log-) gaussian models with informative priors, according to
previously published articles.10 For meta-regression, a linear
model was assumed for the pooled location estimates. For
curve pooling, one meta-analysis was conducted for each
point in a grid and the resulting pooled estimates were then
smoothed by means of lowest regression.
The presence of PAD, defined as ABI <1.00 or ABI >1.40,
was associated with a 31% increase in risk for incident AF
(Table). Considering the 2 ABI classes distinctly, we found that
ABI <1.00 was associated with an increased risk of develop-
ing AF (HR, 1.32; 95% CI, 1.18–1.47), whereas ABI >1.40
class was not associated with an increased risk of AF. A meta-
regression analysis, according to the main demographic
characteristics and cardiovascular risk factors, showed that
no predictor was able to significantly affect the association
between PAD and AF (Table). Similar data were retrieved
when the meta-regression analysis was performed according
to the ABI classes (data not shown). A cumulative cubic spline
model was obtained, pooling together the spline curves from
the 3 studies included in the analysis,6–8 confirming the
inverse dose-effect response between ABI and the risk of
incident AF (Figure 1). The pooled cubic spline also confirmed










3925 vs 22 064 1.32 1.18–1.47
ABI >1.40 vs
ABI 1.00–1.40
516 vs 22 064 1.08 0.86–1.35
Meta-Regression* DHR 95% CI P Value
Age, y 1.001 0.996–1.007 0.419
Follow-up, y 0.999 0.972–1.021 0.819
Male sex, % 1.002 0.994–1.010 0.313
White ethnicity, % 1.000 0.995–1.005 0.687
BMI, kg/m2 1.004 0.990–1.019 0.225
Ever smoker, % 1.001 0.994–1.008 0.483
Diabetes mellitus, % 1.010 0.981–1.038 0.162
SBP, mm Hg 1.001 0.998–1.004 0.443
CHD, % 1.001 0.968–1.029 0.896
Heart failure, % 0.973 0.858–1.097 0.378
Antihypertensive drugs, % 1.002 0.993–1.011 0.287
ABI indicates ankle-brachial index; AF, atrial fibrillation; BMI, body mass index; CHD,
coronary heart disease; CI, confidence interval; HR, hazard ratio; PAD, peripheral artery
disease; and SBP, systolic blood pressure.
*Meta-regression is referred to overall PAD.
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that the risk is still present, despite being lower, in the
borderline ABI class (Figure 1).
Data from our meta-analysis and meta-regression reinforce
and strengthen the evidence about the association between
PAD and AF. The large number of subjects gathered from the
3 studies provide robust confirmation of the strict causal
relationship between the 2 conditions. In all the 3 original
studies, the adjustment with baseline characteristics and
concomitant risk factors mitigates the association; however,
no covariate significantly affected the pooled HR between
PAD and AF. Also, the evidence that although the association
between ABI <1.00 and incident risk of AF is confirmed, our
results gave us the proof that likely the lack of association
between ABI >1.40 and AF is factual. Indeed, gathering >500
subjects, this evidence appears more robust than it was on
the single studies. Last, the pooled cubic spline confirmed
that as much as the vascular disease progresses, the risk is as
high to develop an incident AF episode.
The data gathered from the meta-analysis, discussed in the
context of current knowledge, give us the opportunity to
provide several considerations.
The difference in the association between ABI <1.00 and
ABI >1.40 could be based on the difference in the pathogen-
esis of the vascular disease. The finding of an ABI <1.00 is
based on intimal and endothelial disease, sustained by
systemic atherosclerosis. Conversely, ABI >1.40 represents
arterial stiffening, based on medial wall calcification.1 So, in
subjects with ABI <1.00, the presence of multiple risk factors
carries a relevant inflammatory burden, which triggers
systemic atherosclerosis and, subsequently, generates
PAD.1,11 We can postulate that both the persistence of
inflammatory burden, given by the perpetuating risk factors
and the endothelial dysfunction directly related to systemic
atherosclerosis and PAD presence, could interact together to
influence the onset of AF. Indeed, data indicate the increased
inflammatory burden in patients with AF, connecting the
presence of atherosclerosis and incident AF.12 These postu-
lates are also corroborated by other studies underlining a
strict relationship between another sign of systemic
atherosclerosis, the intima-media thickness, and AF.13,14
From this perspective, we should probably start considering
the onset of AF as the last stage of a multiple-stage process,
spanning throughout the entire lifetime, beginning with the
presence of multiple risk factors and progressing throughout
the development of systemic atherosclerosis and diagnosis of
PAD (Figure 2). This new pathophysiological “paradigm” could
contribute to partially understand the current burden of AF.
Indeed, some data indicate that (subclinical) atherosclerosis is
more likely associated with persistent/permanent AF,14
whereas conversely, paroxysmal AF is more likely associated
with an electrophysiological mechanism.15
Conclusions
The available evidence, as emphasized by our meta-analysis,
strongly underlines the strict causal relationship between PAD
and AF. In the context of the current literature, the data
presented point out how the onset of the arrhythmia could be
considered as the ultimate stage of a multiple-stage disease
process, that starting from the presence of risk factors, leads
to the development of atherosclerosis, diagnosis of PAD, and
incident AF.
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